A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trialTine Ottenbourgs, Toon van Gorp, Frédéric Kridelka, Thaïs Baert, Hannelore Denys, Frédéric Selle, Inge Baas, Anne-Sophie Van Rompuy, Diether Lambrechts, Els Van Nieuwenhuysen
6 March 2024
Staging by imaging in gynecologic cancer and the role of ultrasound: an update of European joint consensus statementsDaniela Fischerova, Carolina Smet, Umberto Scovazzi, Diana Natacha Sousa, Kristina Hundarova, Ingfrid Salvesen Haldorsen
4 March 2024
Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapySergio Cedillo, Carla Garí, Susana Aceituno, Luis Manso, Ana Cristina Cercos Lleti, Pedro Ventayol Bosch, Antonio Casado, Alejandro Perez Fidalgo
2 December 2023
The Womb Cancer Awareness Measure (WCAM): development of an instrument to assess public awareness of endometrial cancerOlivia Jones, Hannah Young, Helen Clarke, Emma J Crosbie, Vanitha N Sivalingam
6 December 2023
Centralizing surgery for ovarian cancer in a ‘non-centralizing’ country (Belgium): the UNGO (UCLouvain Network of Gynaecological Oncology) experienceMathieu Luyckx, Mathieu Jouret, Kismendsida Sawadogo, Marc Waterkeyn, Frédéric Grandjean, Jean-Paul Van Gossum, Nathanael Dubois, Vincent Malvaux, Lucie Verreth, Pascale Grandjean, Annika Malin Bruger, Pascale Jadoul, Charlotte Maillard, Amandine Gerday, Jean-François BaurainSee the full list of authors
16 October 2023
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialDomenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, Claire Cropet, Cristina Caballero, Pia Wolfrum-Ristau, Toyomi Satoh, Ignace Vergote, Gabriella Parma, Trine J Nøttrup, Coriolan Lebreton, Peter A Fasching, Carmela Pisano, Luis Manso, Hugues BourgeoisSee the full list of authors
21 December 2023
Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II studyLingfang Xia, Jing Wang, Chunyan Wang, Qingming Zhang, Jianqing Zhu, Qunxian Rao, Huijun Cheng, Zheng Liu, Yongmei Yin, Xiaohong Ai, Kurban Gulina, Hong Zheng, Xiaoyong Luo, Baoping Chang, Li LiSee the full list of authors
24 October 2023
Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancerBente Vilming, Jørgen Fallås Dahl, Anne Gry Bentzen, Vibeke Anett Ingebrigtsen, Elisabeth Berge Nilsen, Ingvild Vistad, Anne Dørum, Olesya Solheim, Line Bjørge, Manuela Zucknick, Guro Aune, Kristina Lindemann
24 November 2023
Developing a hyperthermic intraperitoneal chemotherapy (HIPEC) gynecologic oncology program: a Canadian experienceJoannie Neveu, Elizabeth Tremblay, Frederic Mercier, Sébastien Garneau, Beatrice Cormier
27 November 2023
Time to extend the indication for sentinel node biopsy in vulvar cancer? Results from a prospective nationwide Swedish studyDiana Zach, Katja Stenström Bohlin, Paivi Kannisto, Louise Moberg, Preben Kjölhede
2 November 2023